デュルバルマブ
2018年9月、「切除不能なステージIII非小細胞肺癌」について承認された。
gov
↑ “AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer”. www.astrazeneca.com. 2021年12月12日閲覧。
↑ “AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress”. www.astrazeneca.com (2017年9月). 2021年12月12日閲覧。
↑ “A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)”.